
  
    
      
        
        Animal_NNP models_NNS can_MD play_VB an_DT essential_JJ role_NN in_IN guiding_VBG preclinical_JJ vaccine_NN development_NN ,_,
        including_VBG in_IN studies_NNS of_IN preclinical_JJ vaccine_NN safety_NN ,_, vaccine_NN toxicity_NN ,_, and_CC vaccine_NN
        immunogenicity_NN ._. Appropriate_NNP pathogen_NN challenge_NN models_NNS can_MD also_RB provide_VB the_DT opportunity_NN to_TO
        perform_VB preclinical_JJ tests_NNS of_IN vaccine_NN efficacy_NN ._. Preclinical_NNP tests_NNS of_IN HIV_NNP vaccine_NN efficacy_NN
        are_VBP usually_RB performed_VBN by_IN exposing_VBG macaques_NNS to_TO simian_NN immunodeficiency_NN virus_NN (_( SIV_NNP )_) ,_, a_DT virus_NN
        that_WDT is_VBZ closely_RB related_VBN to_TO HIV_NNP ._. However_RB ,_, the_DT viral_JJ inoculum_NN sizes_NNS used_VBN to_TO infect_NN macaques_NNS
        with_IN SIV_NNP vastly_RB exceed_VBP the_DT amounts_NNS of_IN HIV_NNP that_IN humans_NNS are_VBP exposed_VBN to_TO during_IN a_DT given_VBN
        exposure_NN ._. Typically_RB animals_NNS are_VBP exposed_VBN to_TO 10_CD –_NN 100_CD times_NNS the_DT infectious_JJ dose_NN at_IN which_WDT 50_CD %_NN of_IN
        the_DT animals_NNS become_VBP infected_JJ (_( ID_NNP 50_CD )_) ._. These_DT excessive_JJ doses_NNS may_MD not_RB provide_VB realistic_JJ
        preclinical_JJ tests_NNS of_IN vaccine_NN efficacy_NN ._. Indeed_RB ,_, no_DT vaccine_NN has_VBZ been_VBN shown_VBN to_TO be_VB effective_JJ in_IN
        preventing_VBG infection_NN by_IN SIV_NNP (_( so-called_JJ sterilizing_VBG immunity_NN )_) in_IN such_JJ high_JJ viral_JJ inoculum_NN
        trials_NNS ._. Now_RB ,_, in_IN a_DT paper_NN published_VBN in_IN 
        PLoS_NNP Medicine_NNP ,_, Roland_NNP Regoes_NNP and_CC colleagues_NNS speculate_VBP that_IN an_DT
        alternative_JJ approach_NN to_TO trials_NNS in_IN animals_NNS not_RB only_RB can_MD mimic_VB the_DT human_JJ patterns_NNS of_IN repeated_VBN
        low-dose_JJ exposure_NN ,_, but_CC also_RB can_MD remove_VB one_CD concern_NN for_IN animal_NN researchers—the_NN need_VBP to_TO use_VB
        very_RB large_JJ numbers_NNS of_IN animals_NNS in_IN experiments_NNS ._.
        What_WP the_DT researchers_NNS did_VBD was_VBD use_NN statistical_JJ power_NN analysis_NN to_TO compare_VB a_DT single_JJ low-dose_JJ
        challenge_NN design_NN ,_, in_IN which_WDT each_DT animal_NN is_VBZ challenged_VBN only_RB once_RB ,_, and_CC a_DT repeated_VBN low-dose_JJ
        challenge_NN design_NN ,_, in_IN which_WDT each_DT animal_NN is_VBZ challenged_VBN until_IN it_PRP is_VBZ infected_VBN or_CC a_DT
        predetermined_VBN maximum_NN number_NN of_IN challenges_NNS is_VBZ reached_VBN ._. The_DT statistical_JJ power_NN of_IN an_DT
        experimental_JJ design—a_NN measure_NN of_IN the_DT statistical_JJ quality—was_NNS assessed_VBN by_IN simulating_VBG
        experiments_NNS ,_, evaluating_VBG them_PRP ,_, and_CC then_RB repeating_VBG the_DT procedure_NN thousands_NNS of_IN times_NNS ._.
        What_WP they_PRP found_VBD was_VBD that_IN the_DT experimental_JJ design_NN using_VBG a_DT single_JJ low_JJ dose_NN of_IN virus_NN in_IN
        each_DT animal_NN required_VBN unfeasibly_RB large_JJ numbers_NNS of_IN animals_NNS ;_: even_RB for_IN the_DT highest_JJS modeled_VBN
        vaccine_NN efficacy_NN of_IN 90_CD %_NN the_DT single_JJ low-dose_JJ challenge_NN design_NN required_VBN more_JJR than_IN 20_CD animals_NNS
        per_IN group_NN to_TO reach_VB a_DT statistical_JJ power_NN of_IN 95_CD %_NN ._. However_RB ,_, when_WRB the_DT researchers_NNS modeled_VBD a_DT
        protocol_NN of_IN repeatedly_RB challenging_VBG the_DT (_( virtual_JJ )_) animals_NNS with_IN a_DT challenge_NN dose_NN of_IN one_CD 
        ID_NNP
        50_CD ,_, and_CC allowing_VBG for_IN a_DT maximum_NN number_NN of_IN 20_CD challenges_NNS of_IN each_DT
        individual_JJ animal_NN ,_, as_RB few_JJ as_IN five_CD animals_NNS were_VBD required_VBN to_TO achieve_VB more_JJR than_IN 95_CD %_NN of_IN
        statistical_JJ power_NN ._.
        Where_WRB do_VBP these_DT results_NNS leave_VBP the_DT design_NN of_IN HIV_NNP trials_NNS ?_. To_TO begin_VB with_IN ,_, the_DT results_NNS should_MD
        encourage_VB researchers_NNS to_TO develop_VB animal_NN models_NNS that_WDT reflect_VBP ,_, to_TO the_DT fullest_JJS extent_NN
        possible_JJ ,_, what_WP is_VBZ known_VBN about_IN the_DT natural_JJ history_NN and_CC pathogenesis_NNS of_IN the_DT disease_NN in_IN
        humans_NNS ,_, rather_RB than_IN designing_VBG trials_NNS to_TO fit_VB the_DT animal_NN models_NNS that_WDT are_VBP available_JJ ._. The_DT
        authors_NNS have_VBP made_VBN available_JJ the_DT programming_NN script_NN of_IN their_PRP$ analysis_NN so_IN anyone_NN can_MD repeat_VB
        it_PRP ;_: it_PRP would_MD be_VB interesting_JJ to_TO know_VB whether_IN preclinical_JJ trials_NNS assessing_VBG vaccines_NNS or_CC
        treatments_NNS against_IN infections_NNS by_IN other_JJ pathogens_NNS could_MD be_VB usefully_RB modeled_VBN in_IN this_DT way_NN as_RB
        well_RB ._.
      
    
  
